John Malysz


Affiliation: Abbott Laboratories
Country: USA


  1. Malysz J, Anderson D, Grønlien J, Ji J, Bunnelle W, Håkerud M, et al. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther. 2010;334:863-74 pubmed publisher
    ..In summary, ABT-107 is a selective high affinity alpha7 nAChR agonist suitable for characterizing the roles of this subtype in pharmacological studies. ..
  2. Malysz J, Grønlien J, Anderson D, Håkerud M, Thorin Hagene K, Ween H, et al. In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile. J Pharmacol Exp Ther. 2009;330:257-67 pubmed publisher
    ..In summary, this study identifies a novel and selective alpha7 PAM showing activity at recombinant and native alpha7 nAChRs exhibiting a unique pharmacological interaction with the receptor. ..
  3. Malysz J, Daza A, Kage K, Grayson G, Yao B, Meyer M, et al. Characterization of human cannabinoid CB2 receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins. Eur J Pharmacol. 2009;603:12-21 pubmed publisher